SLU-PP-332 is a research tool compound in the most literal sense — it was built at Saint Louis University to answer a specific scientific question: what happens if you pharmacologically switch on the transcriptional program that exercise normally triggers? The published research is entirely preclinical, but it's real, peer-reviewed, and mechanistically specific.
What Is SLU-PP-332?
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptor family — ERRα, ERRβ, and ERRγ — with preferential potency at ERRα. ERRs are orphan nuclear receptors (no known endogenous hormone ligand) that sit downstream of PGC-1α, the master regulator of mitochondrial biogenesis.
Mechanism of Action
Activating ERRα with SLU-PP-332 induces an acute aerobic-exercise gene-expression program in skeletal muscle in an ERRα-dependent manner — meaning the effect is lost when the receptor is knocked out, direct evidence the mechanism runs through this receptor and not an off-target pathway. In C2C12 muscle cells, treatment substantially induced mitochondrial biogenesis (confirmed via MitoTracker staining) and increased cellular respiration, consistent with the exercise-program interpretation.
What the Preclinical Research Shows
The published studies span in vitro respiration assays and in vivo mouse metabolic models:
- Increased mitochondrial biogenesis and cellular respiration in C2C12 myoblasts
- Enhanced exercise capacity in mouse models, without the animals actually exercising
- In diet-induced obese and ob/ob (genetically obese) mice: increased energy expenditure and fatty-acid oxidation
- Progressive weight loss and decreased adipocyte size in high-fat-diet-induced obesity models
Every finding above is from mouse models and cell culture. There are no published human trials of SLU-PP-332. It has no approved pharmaceutical analog and has not been reviewed by FDA for any bulk-substance or compounding pathway — a narrower regulatory footprint than BPC-157 or TB-500, not a safer one.
Where to Source SLU-PP-332 for Research
For legitimate research applications, purity and accurate dosing are critical. We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.
View the SLU-PP-332 product page →Frequently Asked Questions
Is SLU-PP-332 an 'exercise pill' that's been tested in humans?
No. The exercise-mimetic effects — increased mitochondrial biogenesis, energy expenditure, and exercise capacity — are documented in mouse and cell-culture models only. No published human trial exists.
How is SLU-PP-332 different from GLP-1 drugs for weight loss?
GLP-1 agonists work primarily by suppressing appetite. SLU-PP-332's studied mechanism increases energy expenditure and fatty-acid oxidation — the metabolic side of the equation exercise normally drives — rather than reducing food intake.
References
1. "Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response." PubMed. pubmed.ncbi.nlm.nih.gov
2. "A Synthetic ERR Agonist Alleviates Metabolic Syndrome." Journal of Pharmacology and Experimental Therapeutics, PubMed. pubmed.ncbi.nlm.nih.gov
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.